The addition of Qfitlia, also known as fitusiran, aims to bypass traditional logistical hurdles. LUX Infusion manages the transition for both new and established patients by leveraging a dedicated benefit and appeals team. According to CEO Ted Kramm, the company’s high-touch service model is intended to simplify navigation for the bleeding disorder community.
In section Releases
LUX Infusion Adds Fitusiran to Hemophilia Treatment Network
Patients aged 12 and older living with hemophilia A or B now have expanded access to Qfitlia, a subcutaneous treatment option. Plantation-based LUX Infusion integrated the therapy into its clinician-led network to streamline the specialized care required for routine bleed prevention, whether patients have Factor VIII or IX inhibitors.
Each patient is assigned a single point of contact with direct experience in bleeding disorders, supported by 24/7 on-call clinical guidance. The program coordinates directly with existing Hemophilia Treatment Centers to maintain continuity of care. Interested providers and patients can initiate the process through the company's portal at luxinfusion.com.
Comments (0)
No comments yet. Be the first!